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remission (CR) cases since late 90´. Early concurrent radiation (RT) 
has been found as slightly beneﬁcial at cost of higher toxicity. This 
strategy has been used for regional treatment protocol since 2000 in 
VFN, University Hospital Prague.
Methods: The planned treatment consisted of 4 to 6 courses of plati-
num/etoposide chemotherapy (CT) and thoracic irradiation concomi-
tantly with the second and third cycle. RT dose 45 to 60 Gy with one 
daily fraction (1.8 - 2.0 Gy) in 5 to 6.5 weeks was prescribed. Patients 
with CR were assigned to PCI (30 Gy in 15 fractions) at the end of 
treatment. Survival, time to progression, local control, relapse pattern 
and toxicity data were collected. Possible prognostic factors as sex, 
age, concurrent RT yes or not, treatment response, PCI yes or not, were 
tested for survival impact.
Results: 53 consecutive patients were treated between Jan-2000 and 
Dec-2006, 31 men, 22 women, and median age 63 years (range 49 
- 80). CT in median dose of 5 cycles was predominantly cisplatin based 
(64%), RT in median dose of 55,8 Gy was given concurrently in 26 
(49%) of patients and sequentially in 19 (36%). Sequential strategy was 
preferred due to age over 70 or worse performance status. Thoracic RT 
was omitted in 8 patients, for poor performance status or progressive 
disease in 5 and due to radical surgery in 3 subjects. Esophagitis grade 
3-4 occurred in 43%, signiﬁcantly more often in concurrent RT (61% 
vs. 21%, p < 0.01). Early radiation pneumonitis of any grade occurred 
in 5%. Response rate (RR) 92% and CR 61% in concurrent group did 
not differ signiﬁcantly from sequential one (RR 89%, CR 53%). The 
median survival was 19 months and 3- and 5-year survival was 26% in 
all the patients. Survival differences in groups according to sex, age, 
partial versus complete treatment response or concurrent radiation 
delivery did not differ signiﬁcantly. Meaningful survival difference was 
observed between groups with PCI yes or not (3-and 5-year survival 
52% versus 18%), but without statistical signiﬁcance (p = 0.067). 
The median time to progression was 14 months for the whole group. 
Signiﬁcantly longer time to progression was in CR patients and PCI 
patients. Patterns of relapses were local only in 19%, distant with local 
progression 17%, distant only in 64%. Brain metastases were ﬁrst place 
of relapse in 13% of all patients (20% in non-PCI group) but none of 
18 (34%) PCI patients have had brain relapse. Intercurrent disease was 
cause of death in 7% of pts.
Conclusions: Concurrent early chemoradiotherapy in LD SCLC pa-
tients did not conﬁrm clear survival beneﬁt against sequential strategy 
in our group, probably for small number of subjects and high distant 
relapse rate, further investigation is warranted. PCI delivery has shown 
statistically signiﬁcant impact on time to progression and trend to lon-
ger overall survival and should be offered also to PR patients.
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Introduction: Preventive cranial irradiation (PCI) in patients (pts) 
with small-cell lung cancer (SCLC) decreases the overall rate of brain 
metastases, as shown by several randomized trials conducted in the 
1970s and 1980s. Results from retrospective data suggested a potential 
survival beneﬁt restricted to patients in complete remission. 
Purpose: To evaluate the effects of PCI on the rates of brain metasta-
ses and overall survival in patients with stage I-III SCLC after radical 
operations. 
Patients and methods: Since 2000, 40 pts with SCLC after radical 
operations were eligible for inclusion in a randomized trial. Their mean 
age was 57.01+1.05. The pts distribution by tumor extension was as 
follows: T1N0 - 1(2.5%), T2N0 - 2 (5.0%), T1N1 - 2 (5.0%), T2N1 - 7 
(17.5%), T3N0 - 1 (2.5%), T1N2 - 2 (5.0%), T2N2 - 15 (37.5%), T3N1 
- 3 (7.5%), T3N2 - 3 (7.5%), T4N2 - 2 (5.0%) and T2N3 - 2 (5.0%). 
After surgery all the pts were randomized to receive either 4 courses 
of adjuvant chemotherapy (ChT) including Cisplatin+VP-16 with PCI 
at a total dose of 30 Gy (a dose per fraction equal to 2 Gy) for 15 days, 
5 fractions per week (PCI group) or without PCI (control group). The 
interval between ChT courses was 3 weeks. For radiation treatment, the 
target volume was the whole brain. All the pts gave informed consent 
to participate. 20 pts were assigned to the PCI group and 20 to the 
control group. 16 (80.0%) pneumonectomies and 4 (20.0%) lobecto-
mies were perfomed in the control group. The respective ﬁgures in the 
PCI group were 15 (75.0%) and 5 (25.0%). No differences were found 
in the extent of tumor spread, its site, clinicoanatomical form and the 
affected side. 
Results: According to the data obtained, the overall rate of brain 
metastases for the pts in the control group was 15% vs 0.0%for the 
pts in the PCI group. In no case CT detected any changes in the brain 
structures. Two-year follow-up of the pts without signs of metastatic 
involvement of the brain after irradiation found no abnormalities in the 
neurological status. Overall two-year survival was 67.5+10.1%, this 
rate in the PCI and control groups being 66.7+14.6% I 62.9+14.5% 
respectively. 
Conclusions: The evidence provided suggests that surgery with 
adjuvant chemotherapy and PCI decreases the overall rate of brain 
metastases in SCLC. 
SCLC: Cytotoxic Chemotherapy
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Option: Intensiﬁed treatment should be a rational treatment option in 
SCLC with respect to the pronounced sensitiviy to chemotherapy in 
primary treatment. However, convincing results have not been pre-
sented, so intensiﬁed treatment is not used routinely.
Background: Many studies have compared intensiﬁed, dose-dense and 
higher dose and multiple drug treatment with standard treatment. The 
results differ and e.g. high dose with stem cell rescue has not been a 
